The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Revenue reached $17.8 billion ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Related: Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance "We expect sales of the COVID-19 vaccine to eventually stabilize, and these sales could provide cash flow for ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Total revenue of $17.8 billion in the quarter ... Despite a drop in legacy product sales like Xeljanz, Pfizer demonstrated resilience through effective cost management. Notably, Pfizer's R&D ...

Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products topped expectations and its broad cost-cutting efforts took hold.

Related: Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance "We expect sales of the COVID-19 vaccine to eventually stabilize, and these sales could provide cash flow for ...